Feussner G, Wagner A, Ziegler R
Abteilung Innere Medizin I, Schwerpunkt Endokrinologie und Stoffwechsel, Medizinische Universiätsklinik Heidelberg, Germany.
Hum Genet. 1993 Sep;92(2):122-6. doi: 10.1007/BF00219678.
The familial lipoprotein disorder type III hyperlipoproteinemia (HPL) carries a marked increase in the risk of accelerated and premature atherosclerosis, but there is considerable variation among affected individuals in susceptibility to cardiovascular disease (CVD). We studied the influence of independent risk factors for atherosclerosis in 67 patients with clinically overt type III HPL and homozygosity for apolipoprotein (apo) E2. Among the different risk factors (lipid and lipoprotein levels, age, sex, body mass index, smoking status, hypertension, and diabetes mellitus) there was only a statistically significant difference in age between 25 patients with atherosclerosis and 42 patients without atherosclerosis. Serum lipoprotein (a), [Lp, (a)], levels were 30.6% higher in the atherosclerosis group, but this was not statistically significant. We conclude that (in contrast to familial hypercholesterolemia) elevated Lp (a) concentrations may not be regarded as a component of the clinical syndrome of type III HPL.
家族性脂蛋白紊乱III型高脂蛋白血症(HPL)会显著增加加速性和早发性动脉粥样硬化的风险,但在受影响个体中,对心血管疾病(CVD)的易感性存在相当大的差异。我们研究了67例临床显性III型HPL且载脂蛋白(apo)E2纯合的患者中动脉粥样硬化独立危险因素的影响。在不同的危险因素(血脂和脂蛋白水平、年龄、性别、体重指数、吸烟状况、高血压和糖尿病)中,25例有动脉粥样硬化的患者和42例无动脉粥样硬化的患者之间仅年龄存在统计学显著差异。动脉粥样硬化组的血清脂蛋白(a)[Lp,(a)]水平高30.6%,但这无统计学显著性。我们得出结论,(与家族性高胆固醇血症不同)Lp(a)浓度升高可能不能被视为III型HPL临床综合征的一个组成部分。